Placental Repair Using Organoid Models: A PubMed-Grade Scientific Review

Abstract

Placental dysfunction is implicated in a spectrum of pregnancy complications and adverse fetal outcomes. Conventional models to study placental repair have significant limitations, impeding translational progress. The advent of organoid technology offers a transformative platform for modeling placental development and pathology, as well as exploring targeted repair strategies. This review synthesizes current evidence on placental repair using organoid models, outlines their mechanistic underpinnings, clinical relevance, and discusses future directions for implementation in research and clinical practice.

Introduction

The placenta is essential for fetal growth, nutrient exchange, and immunological tolerance during gestation. Placental insufficiency is central to conditions such as preeclampsia, fetal growth restriction, and stillbirth. Despite its clinical significance, research into placental repair has been hampered by limited access to viable human tissue and the inadequacy of animal models to fully recapitulate human placental physiology. Recent advances in three-dimensional (3D) organoid technology have enabled the culture of self-organizing placental tissues in vitro, providing unprecedented opportunities for mechanistic studies and therapeutic innovation. This review integrates recent findings on placental organoid models, emphasizing their role in advancing the understanding and treatment of placental disorders.

Epidemiology / Disease Burden

Placental disorders contribute substantially to maternal and perinatal morbidity and mortality worldwide. Preeclampsia affects 2-8% of pregnancies, while placental insufficiency is a leading cause of intrauterine growth restriction (IUGR) and preterm birth. Stillbirth due to placental dysfunction remains a global challenge, notably in low-resource settings. The inability to effectively repair or regenerate dysfunctional placental tissue underlies the persistent burden of these complications. The epidemiological impact underscores the urgent need for robust research models to facilitate therapeutic discovery and improve outcomes for mothers and infants.

Pathophysiology

Placental dysfunction arises from abnormal trophoblast proliferation, differentiation, and invasion, leading to impaired vascularization and nutrient exchange. Disrupted interactions between maternal decidua and trophoblasts result in defective spiral artery remodeling—a hallmark of preeclampsia and IUGR. Aberrant expression of angiogenic factors, excessive oxidative stress, and dysregulated immune responses further contribute to pathological placentation. Traditional in vitro models fail to replicate the complex 3D architecture and cellular diversity of the human placenta, limiting mechanistic insights. Organoid models, derived from stem or progenitor cells, can recapitulate key structural and functional aspects of the placenta, providing a physiologically relevant system to dissect these mechanisms and test repair strategies.

Risk Factors

Risk factors for placental dysfunction include advanced maternal age, pre-existing hypertension, diabetes, obesity, autoimmune disease, and multiple gestation. Genetic predisposition, abnormal uterine anatomy, and environmental exposures (such as smoking or pollution) further increase vulnerability. These risk factors contribute to the heterogeneous presentation of placental disorders and complicate the development of universal therapeutic interventions. Organoid models enable the study of patient-specific risk profiles and facilitate the identification of molecular signatures associated with increased risk, paving the way for precision medicine approaches in placental repair.

Clinical Features

Clinical manifestations of placental dysfunction range from asymptomatic abnormal Doppler findings to overt preeclampsia, IUGR, preterm labor, and fetal demise. Maternal symptoms may include hypertension, proteinuria, and edema, while fetal consequences encompass growth restriction, oligohydramnios, and non-reassuring fetal heart patterns. The variable clinical spectrum reflects the degree and timing of placental injury. Accurate assessment of placental health remains challenging, highlighting the need for improved biomarkers and functional assays, which organoid models may help develop and validate.

Diagnosis

Diagnosis of placental disorders relies on clinical assessment, ultrasonography, Doppler flow studies, and emerging biomarkers such as placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). Histopathological analysis post-delivery remains the gold standard for confirming placental lesions. Organoid-derived tissues can serve as innovative platforms for biomarker discovery, validation, and the development of functional diagnostic assays. By mimicking in vivo placental physiology, organoids offer enhanced fidelity for studying disease-specific signatures and therapeutic responses in a controlled environment.

Treatment & Management

Current management of placental dysfunction is largely supportive, focusing on maternal blood pressure control, fetal surveillance, and timely delivery. Pharmacologic interventions to restore placental function are limited, and no therapies currently exist to repair the placenta in situ. The inability to directly modulate placental pathology highlights the need for novel strategies. Organoid models provide a preclinical platform for high-throughput drug screening, gene editing, and regenerative approaches, enabling the rational design of targeted therapies aimed at restoring placental architecture and function.

Recent Advances / Emerging Therapies

Placental organoids have emerged as a promising tool for studying trophoblast development, cell-cell interactions, and disease modeling. By leveraging induced pluripotent stem cells (iPSCs) or primary trophoblasts, researchers can generate 3D mini-placentas that faithfully recapitulate villous structure, hormone secretion, and barrier functions. Recent studies have demonstrated the utility of organoids in modeling preeclampsia, Zika virus infection, and genetic placental disorders. CRISPR/Cas9-mediated gene editing in organoids enables functional validation of candidate genes implicated in placental disease. Furthermore, co-culture systems incorporating maternal immune or endothelial cells provide insights into cross-talk mechanisms and reparative responses. Ongoing research aims to harness organoid platforms for personalized medicine, drug development, and regenerative therapies targeting placental repair.

Guideline Recommendations

International guidelines currently emphasize prevention, early detection, and risk stratification for placental disorders, given the lack of curative therapies. However, leading bodies such as the International Federation of Gynecology and Obstetrics (FIGO) and the American College of Obstetricians and Gynecologists (ACOG) recognize the potential of advanced models, including organoids, for research and therapeutic innovation. Incorporation of organoid-based findings into clinical practice awaits further validation and regulatory approval but represents a key future direction in the field.

Conclusion

Placental repair using organoid models represents a significant leap forward in reproductive medicine. These models bridge critical gaps in our understanding of placental development, pathophysiology, and therapeutic response. While challenges remain in translating organoid-based discoveries to clinical applications, ongoing advances herald a new era of precision placental medicine with the promise of improved outcomes for mothers and infants. Continued interdisciplinary research and integration of organoid technology into translational pipelines will be pivotal for realizing their full potential in placental repair.